Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

References

• SuhJH, JohnsonA, AlbackerL, et al. Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism‐driven clinical trials. Oncologist. 2016;21(6):684–691. doi:10.1016/j.jtho.2016.11.181827151654
   PubMed Web of Science ®Google Scholar
• MurtuzaA, BulbulA, ShenJP, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79(4):689–698. doi:10.1158/0008-5472.can-18-128130718357
   PubMed Web of Science ®Google Scholar
• WangY, WangY, LiJ, LiJ, CheG. Clinical significance of PIK3CA gene in non-small-cell lung cancer: a systematic review and meta-analysis. Biomed Res Int. 2020;2020:1–9. doi:10.1155/2020/3608241
   Web of Science ®Google Scholar
• SongZ, YuX, ZhangY. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Med. 2016;5(10):2694–2700.doi. doi:10.1002/cam4.85227554588
   PubMed Web of Science ®Google Scholar
• JinY, BaoH, LeX, et al. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene. 2019;39(9):1846–1859. doi:10.1038/s41388-019-1104-z31754213
   PubMed Web of Science ®Google Scholar
• RebuzziSE, AlfieriR, La MonicaS, MinariR, PetroniniPG, TiseoM. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol. 2020;146:102820. doi:10.1016/j.critrevonc.2019.10282031785991
   PubMed Web of Science ®Google Scholar
• HanB, JinB, ChuT, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int J Cancer. 2017;141(6):1249–1256. doi:10.1002/ijc.3080628560853
   PubMed Web of Science ®Google Scholar
• AmosC, TsongalisG, DeharvengtS, et al. Identifying associations between somatic mutations and clinicopathologic findings in lung cancer pathology reports. Methods Inf Med. 2018;57(01/02):63–73. doi:10.3414/me17-01-003929621832
   PubMed Web of Science ®Google Scholar
• MilanoG. PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting. Cancer Chemother Pharmacol. 2020;85(2):473–474. doi:10.1007/s00280-019-04016-931970497
   PubMed Web of Science ®Google Scholar
• BlakelyCM, WatkinsTBK, WuW, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693–1704.doi. doi:10.1038/ng.399029106415
   PubMed Web of Science ®Google Scholar
• AredoJV, PaddaSK, KunderCA, et al. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer. 2019;133:144–150. doi:10.1016/j.lungcan.2019.05.01531200821
   PubMed Web of Science ®Google Scholar
• LangerCJ, RedmanMW, WadeJL, et al. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thoracic Oncol. 2019;14(10):1839–1846. doi:10.1016/j.jtho.2019.05.029
   PubMed Web of Science ®Google Scholar
• VansteenkisteJF, CanonJL, De BraudF, et al. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: results from the Phase II BASALT-1 Study. J Thorac Oncol. 2015;10(9):1319–1327. doi:10.1097/JTO.000000000000060726098748
   PubMed Web of Science ®Google Scholar
• ZhouX, WangX, ZhuH, et al. PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy. Exp Ther Med. 2021;21(1):9. doi:10.3892/etm.2020.944133235618
   PubMed Web of Science ®Google Scholar
• BorcomanE, De La RochereP, RicherW, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 2019;8(5):e1581556. doi:10.1080/2162402X.2019.158155631069145
   PubMed Web of Science ®Google Scholar
• Kauffmann-GuerreroD, TufmanA, KahnertK, et al. Response to checkpoint inhibition in non-small cell lung cancer with molecular driver alterations. Oncol Res Treatment. 2020;43(6):289–298. doi:10.1159/000506842
   PubMed Web of Science ®Google Scholar
• GuoYJ, SongJ, WangY, et al. Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review. Front Oncol. 2020:10. doi:10.3389/fonc.2020.610923.32047721
   PubMed Web of Science ®Google Scholar
• VanderlaanP, RangachariD, MockusS, et al. P1.02-031 Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. J Thoracic Oncol. 2017;12(1):S506. doi:10.1016/j.jtho.2016.11.614
   Web of Science ®Google Scholar
• ChangWJ, SungJS, LeeSY, et al. The clinical significance of RAS, PIK3CA, and PTEN mutations in non-small cell lung cancer using cell-free DNA. J Clin Med. 2020;9(8):2642. doi:10.3390/jcm9082642
   PubMed Web of Science ®Google Scholar
• YangX, XiaY, XuL, et al. Efficacy and safety of combination treatment with apatinib and osimertinib after osimertinib resistance in epidermal growth factor receptor-mutant non-small cell lung carcinoma-A retrospective analysis of a multicenter clinical study. Front Mol Biosci. 2021;8:639892.doi. doi:10.3389/fmolb.2021.639892
   Web of Science ®Google Scholar
• WuY, HuangJ, WangQ, et al. Whole-exome sequencing insights into pulmonary artery sarcoma mimicking pulmonary embolism: a case report and review. Onco Targets Ther. 2019;12:6227–6235.doi. doi:10.2147/OTT.S21241631496726
   PubMed Web of Science ®Google Scholar
• JonaschE, HasanovE, CornPG, et al. A randomized Phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017;28(4):804–808. doi:10.1093/annonc/mdw67628049139
   PubMed Web of Science ®Google Scholar
• ChiY, FangZ, HongX, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-376629895706
   PubMed Web of Science ®Google Scholar
• ShenHB, LiJ, YaoYS, et al. Impact of somatic mutations in non-small-cell lung cancer: a retrospective study of a Chinese cohort. Cancer Manag Res. 2020;12:7427–7437. doi:10.2147/cmar.s25413932884354
   PubMed Web of Science ®Google Scholar
• LeiL, WangW, ZhuY, et al. Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: a multi‐center study. Cancer Sci. 2020;111(2):679–686. doi:10.1111/cas.1427731828849
   PubMed Web of Science ®Google Scholar